Evidence map›Paper›PMID 39412609›Full record

Trial reportEndocrine2025

Elevated circulating regenerating islet-derived protein 4 levels in patients with metabolic syndrome and related to its key components.

Tianjiao Shen, Yu Yang, Yerui Lai, Hongmin Zhang, Dongfang Liu, Cong Wang, Ling Li, Weiwei Xu, Ke Li, Shengbing Li and 1 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tianjiao Shen *Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Yu Yang *Department of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Yerui LaiDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Hongmin ZhangDepartment of Endocrinology, People's Hospital of Chongqing Liang Jiang New Area, Chongqing, China.
Dongfang LiuDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Cong WangDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Ling LiKey Laboratory of Diagnostic Medicine (Ministry of Education) and Department of Clinical Biochemistry, College of Laboratory Medicine, Chongqing Medical University, Chongqing, China.
Weiwei XuDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. xuweiwei@hospital.cqmu.edu.cn.
Ke LiDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Shengbing LiDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. 302122@hospital.cqmu.edu.cn.
Mengliu YangDepartment of Endocrinology, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. mengliu.yang@cqmu.edu.cn.

Funding

National Natural Science Foundation of China 82100852Natural Science Foundation of Chongqing CSTB2022NSCQ-MSX1522
6 · The paper itself

Abstract

purposeRegenerating islet-derived protein 4 (REG4) is a secretory protein that belongs to the C-type lectin superfamily. This study aims to explore the diagnostic value of REG4 as a potential biomarker for metabolic syndrome by analyzing the correlation between serum REG4 levels and metabolic syndrome.

methodsSerum REG4 levels were measured using enzyme-linked immunosorbent assay (ELISA). Bioinformatics analysis was conducted to investigate REG4-related genes and metabolic signaling pathways.

resultsSerum REG4 levels were significantly elevated in MetS patients compared to healthy controls (439.7 vs. 422.6 ng/L, p < 0.01). In addition, circulating REG4 levels showed a positive correlation with AUGg, HbA1c, VAI, BMI, WHR, TG, TC, LDL-C, while being inversely correlated with HDL-C in the study population. Serum REG4 levels were positively correlated with MetS score. Multiple linear regression analysis identified HOMA-IR and LDL-C as independent factors affecting serum REG4 concentration. Interventional studies have shown that OGTT can significantly increase serum REG4 levels in healthy individuals, but significantly reduce REG4 levels in MetS patients. Bioinformatics analysis suggested that REG4 is linked to several metabolism-related genes and is enriched in various metabolism-related signaling pathways.

conclusionREG4 may serve as a valuable biomarker and potential treatment target for insulin resistance (IR) and MetS. CLINICAL TRIAL REGISTRATION NUMBER: ChiCTR2000032878.

Indexed as

Lectins, C-TypeMetabolic SyndromePancreatitis-Associated ProteinsAdultAgedBiomarkersFemaleHumansInsulin ResistanceMaleMiddle AgedBiomarkersLectins, C-TypePancreatitis-Associated ProteinsBioinformatics analysisInsulin resistanceMetSREG4

Identifiers

PMID39412609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.